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Abstract Endocannabinoids contract, relax or do not affect
vessels with different calibre and tone in the pulmonary cir-
culation in four species. The aim of the present study was to
determine the mechanisms involved in the anandamide-
induced relaxation of human pulmonary arteries (hPAs).
Studies were performed in the isolated hPAs pre-constricted
with the prostanoid TP receptor agonist, U-46619. To detect
fatty acid amide hydrolase (FAAH) expression, Western blots
were used. Anandamide concentration dependently relaxed
the endothelium-intact hPAs pre-constricted with U-46619.
The anandamide-induced relaxation was virtually abolished
by removal of the endothelium and strongly attenuated by
inhibitors of cyclooxygenases (indomethacin, COX-1/COX-
2, and nimesulide, COX-2), nitric oxide synthase (NG-nitro-L-
arginine methyl ester) given separately or in combination,
FAAH (URB597), and the prostanoid IP receptor antagonist,
RO1138452. The anandamide-evoked relaxation in the
endothelium-intact vessels was attenuated in KCl pre-
constricted preparations or by the inhibitor of large-
conductance Ca2+-activated K+ channels, iberiotoxin. In ex-
periments performed in the presence of URB597 to exclude
effects of anandamide metabolites, the antagonist of the en-
dothelial cannabinoid receptor, O-1918, diminished the
anandamide-evoked relaxation whereas the antagonists of
cannabinoid CB1, CB2 and vanilloid TRPV1 receptors,
AM251, SR144528 and capsazepine, respectively, had no
effect. Western blot studies revealed the occurrence of
FAAH protein in the hPAs. The present study shows that
anandamide breakdown products, cyclooxygenase pathways,
nitric oxide, potassium channels and the O-1918-sensitive
cannabinoid receptor play a role in the anandamide-induced
relaxation of the hPAs with intact endothelium.
Keywords Human pulmonary artery . Anandamide . Nitric
oxide . Prostacyclin . Potassium channels . O-1918-sensitive
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Introduction
Pulmonary arterial hypertension (PAH) is a progressive, po-
tentially lethal disease. Patients with PAH have increased
levels of potent vasoconstrictors and decreased levels of the
endothelial vasodilator nitric oxide (NO) and prostacyclin
(PGI2), leading to enhanced vasoconstriction, thrombosis,
and pulmonary vascular remodelling (Frumkin 2012).
Available therapies for PAH target the imbalance of
vasoconstricting and vasodilating mediators leading to vaso-
relaxation in pulmonary vasculature (Frumkin 2012; Waxman
and Zamanian 2013; Benyahia et al. 2013). However, to date,
PAH is incurable with the currently approved medications,
and there is an urgent need for alternative treatment strategies.
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Hornig (2007) has suggested that endocannabinoids may rep-
resent a future option in the PAH therapy.
The two best known endocannabinoids, anandamide
( N - a r a c h i d o n o y l e t h a n o l a m i n e ) a n d 2 -
arachidonoylglycerol (2-AG), influence the diameter of
systemic blood vessels by various mechanisms
(Montecucco and Di Marzo 2012), and their possible
role has also been studied in the pulmonary vasculature.
Endogenous anandamide was detected in the lung of the
rabbit (Wahn et al. 2005), the mouse (Wenzel et al.
2013) and the rat (Calignano et al. 2000), and endoge-
nous 2-AG was found in the rabbit lung (Wahn et al.
2005). Moreover, fatty acid amide hydrolase (FAAH),
the enzyme responsible for anandamide degradation,
was detected in rabbit and murine lungs (Wahn et al.
2005; Wenzel et al. 2013) and in human pulmonary
artery smooth muscle cells (Meng et al. 2008; Wenzel
et al. 2013). However, only few functional studies
concerning direct actions of endocannabinoids on the
pulmonary vasculature have been published in the latter
four mammalian species in vivo or in vitro.
In the isolated, ventilated, and buffer-perfused lung of the
rabbit, both anandamide and 2-AG increased the pulmonary
arterial pressure whereas R-methanandamide (a metabolically
stable analogue of anandamide) and noladin ether, a third
endocannabinoid (which is also metabolically stable), failed
to do so (Wahn et al. 2005). These data are similar, although
not identical, to those obtained in the isolated perfused lung
system of mice where anandamide but not 2-AG or R-
methanandamide increased the pulmonary arterial tone
(Wenzel et al. 2013). The explanation for the vasopressor
effect of anandamide is that this endocannabinoid is degraded
by FAAH into arachidonic acid products which in turn are
converted to vasoactive agents by cyclooxygenase-2 (COX-2)
(Wahn et al. 2005) and COX and/or lipooxygenase (Wenzel
et al. 2013). The involvement of cannabinoid CB1 receptors
could be discarded in the rabbit and mouse lungs (Wahn
et al. 2005; Wenzel et al. 2013). With respect to the
rabbit lung, the vanilloid transient receptor potential cat-
ion channel of V1 type (TRPV1) receptor could also be
excluded (Wahn et al. 2005), which, like CB1 or CB2
receptors, is a typical target of anandamide and is known
to elicit dilatation in some vascular beds of the systemic
circulation (for review, see Montecucco and Di Marzo
2012). On the other hand, in another preparation of
rabbits, i.e. pre-constricted, isolated pulmonary arteries,
noladin ether relaxed the rabbit pulmonary artery smooth
muscle (Su and Vo 2007). Two mechanisms are involved
in the latter effect, namely, the activation of cannabinoid
CB1 receptors and, in addition, the activation of O-1918-
sensitive receptors. The molecular and biological proper-
ties of the latter receptors that have been identified in a
series of vascular beds of the systemic circulation
(Montecucco and Di Marzo 2012) are so far poorly
understood.
The effect of endocannabinoids has also been studied in
isolated pulmonary arteries of mice, rats and humans. In non-
pre-constricted preparations of rats and mice, anandamide was
devoid of an effect (Baranowska-Kuczko et al. 2012; Wenzel
et al. 2013). On the other hand, anandamide induced a
vasorelaxant effect in pre-constricted pulmonary arteries from
rats (Baranowska-Kuczko et al. 2012) and humans
(Kozłowska et al. 2007). In rat pulmonary arteries, this effect
involves O-1918-sensitive but not CB1 and TRPV1 receptors;
in addition, COX products play an important role
(Baranowska-Kuczko et al. 2012). With respect to human
pulmonary arteries (hPAs), virodhamine (a fourth
endocannabinoid) shows a vasorelaxant effect again related
to the activation of O-1918-sensitive receptors and the forma-
tion of COX products (Kozłowska et al. 2008). Our previous
data (Kozłowska et al. 2008) do not allow to concludewhether
CB1 and TRPV1 receptors play a role as well since
virodhamine has a low or missing intrinsic activity at CB1
receptors and does not bind to TRPV1 receptors (for review,
see Pertwee et al. 2010). Moreover, anandamide, which
showed a vasodilatory effect as well, has been studied in the
presence of a CB1 receptor antagonist only, and the mecha-
nisms of its vascular effect have not been examined
(Kozłowska et al. 2007). So, the aim of the present study
was to examine the receptors and mechanisms involved in
the effect of anandamide in hPAs. We found that the
anandamide-induced vasorelaxation is strongly endothelium
dependent and involves arachidonic acid degradation prod-
ucts, NO and big-conductance Ca2+-activated K+ channels
(BKCa) and, in addition, is related to the activation of
O-1918-sensitive receptors but not cannabinoid CB1, CB2 or
vanilloid TRPV1 receptors.
Materials and methods
All protocols were approved by the Human Ethical
Committee of the Medical University of Białystok (no. R-I-
002/309/2008). Tissue donors had provided informed consent
for the use of their vessels.
Pulmonary artery preparation
Human lung tissue was obtained from 41 patients (35 men and
6 women, mean age of 66.4±0.7 years including 88 %
smokers) undergoing lobectomy or pneumonectomy during
resection of lung carcinoma. Pre-operative echocardiography
revealed normal left and right ventricular function in each
case. Patients did not have any clinical evidence of pulmonary
hypertension. Before the operation, all patients received ceph-
alosporins and low-molecular-weight heparin as infection and
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thrombosis prophylaxis, respectively. The tissue was
transported to the laboratory within half an hour in a cold
(4 °C), pre-gassed Tyrode’s bicarbonate solution (for compo-
sition, see below at section “Organ bath technique”). Lobar
and segmental hPA branches were cleaned from the lung
parenchyma and cut into rings (from the middle portion of
each artery, 3- to 5-mm length and 2- to 4-mm outer diameter).
Organ bath technique
The arterial rings were suspended on stainless steel wires in
10-ml organ baths containing Tyrode’s solution (concentration
inmillimolar: NaCl, 139.2; KCl, 2.7; CaCl2, 1.8;MgCl2, 0.49;
NaHCO3, 11.9; NaH2PO4, 0.4; glucose, 5.5) and were gassed
continuously with 95%O2 and 5%CO2, at 37 °C and pH 7.4.
Pulmonary artery rings were allowed to equilibrate for 90min;
during this time period, the bath fluid was exchanged every
10 min with fresh Tyrode’s solution. The optimal resting
tension was about 20–25mN (depending on the rings’ internal
diameter), which ensured that responses to agonists were
maximal. Muscle tension was recorded by a force displace-
ment transducer (PIM 100RE, BIO-SYS-TECH, Białystok,
Poland) and displayed on a computer.
After the equilibration period, all rings were pre-constricted
sub-maximally with (–) phenylephrine (1 μM) to prime the
tissues and to assess the integrity of the endothelium (at least
80 % relaxation in response to acetylcholine 1 μM was
designated as endothelium-intact). When necessary, the endo-
thelium was removed by gentle rubbing of the intima. The
absence of acetylcholine-induced vasorelaxation was verified
as successful endothelial denudation.
Viable vessels were constricted sub-maximally with
U-46619 (0.01–0.03 μM; a prostanoid TP receptor agonist).
In some experiments, serotonin (5-HT, 1 μM) or high-KCl
(60mM) Tyrode’s solution prepared by equimolar substitution
of NaCl by KCl was used to pre-constrict the rings. When a
stable level of tone was maintained (after about 45 min of
exposure time), concentration-response curves (CRCs) were
generated by cumulative application of anandamide. The ag-
onist was added in steps of 0.5 log units with about 8–10 min
between each application. Controls were obtained by the
addition of Tocrisolve. All experiments were performed in
paired vessels; control and anandamide-treated responses
were studied on vessels from the same patient. Only one curve
was determined in each individual preparation. In an addition-
al series of experiments, complete CRCs of U-46619 were
recorded 30 min after administration of anandamide 10 μMor
Tocrisolve.
To determine the mechanisms of the vasorelaxant effects of
anandamide, some tissues were pre-treated for 30 min (if not
stated otherwise) with the following antagonists/inhibitors
alone or in combination (details are provided in brackets):
30-min treatment with AM251 1 μM (cannabinoid CB1
receptor), SR144528 1 μM (CB2 receptor), O-1918 10 μM
(endothelial cannabinoid receptor), RO1138452 1 μM (pros-
tanoid IP receptor), URB597 1 μM (FAAH), 45-min incuba-
tion with capsazepine 1 μM (vanilloid TRPV1 receptor),
indomethacin 10 μM (COX-1/COX-2), nimesulide 10 μM
(COX-2), NG-nitro-L-arginine methyl ester (L-NAME)
300 μM (NO synthase), and iberiotoxin 0.1 μM (large-con-
ductance Ca2+-activated K+ channels). Antagonists/inhibitors
were also present during the construction of the CRCs.
The resting tension was not affected by most of the drugs
but slightly decreased by nimesulide and ethanol. Therefore,
slightly different U-46619 concentrations (0.01–0.03 μM)
were used in experiments with the latter agents to achieve
comparable contraction levels (see Table 1 for details).
URB597, RO1138452, capsazepine, nimesulide and O-1918
were dissolved in ethanol, and the effects of the appropriate
vehicle on the relaxation to anandamide were also tested when
the final bath concentration exceeded 0.1 % (v/v). No signif-
icant effects of vehicle on the CRCs were observed (see
Table 1 for details).
Preparation of tissue extracts
The hPAs and lungs were homogenized (20 %w/v) in
0.05 mol/l Tris-HCl, pH 7.6, with the use of a knife homog-
enizer (Polytron) and were subsequently sonicated at 0 °C.
Homogenates were centrifuged at 16,000×g for 30 min at
4 °C. The supernatant was used for protein determination
(Bradford method) and Western blot analysis.
Western blot analysis
Slab sodium dodecyl sulphate polyacrylamide gel electropho-
resis (SDS/PAGE) was used, according to the method by
Laemmli (1970). Equal amounts (about 100 μg) of protein
were electrophoresed. After SDS/PAGE, the gels were
allowed to equilibrate for 5 min in 25 mM Tris plus 0.2 M
glycine in 20 % (v/v) methanol. The proteins were transferred
to 0.2μmpore-sized nitrocellulose at 25mA for 1 h by using a
LKB 2117 Multiphor II electrophoresis unit. The nitrocellu-
lose was incubated with rabbit polyclonal anti-FAAH anti-
body at a concentration of 1:500 and rabbit polyclonal anti-β-
actin antibody at a concentration of 1:500 in 5 % dried milk in
Tris-buffered saline with Tween 20 (TBS-T) (20mMTris-HCl
buffer, pH 7.4, containing 150 mM NaCl and 0.05 % Tween
20) overnight. In order to analyze FAAH and β-actin, a
second antibody, i.e. anti-rabbit IgG (whole molecule) conju-
gated with alkaline phosphatase, was added at a concentration
of 1:5000 in TBS-T and incubated for 1 h under continuous
shaking. Then nitrocellulose was washed with TBS-T (5×
10 min) and submitted to 5-bromo-4-chloro-3-indolyl
phosphate/nitro blue tetrazolium (BCIP/NBT) liquid substrate
reagent.
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Drugs used
Acetylcholine chloride, (–) phenylephrine hydrochloride, se-
rotonin (creatinine sulphate complex) and L-NAME (Sigma,
Munich, Germany) were dissolved in deionized water.
Indomethacin (Sigma) was dissolved in 0.5 M NaHCO3.
Anandamide was purchased from Tocris (Bristol, UK) as a
10-mg/ml emulsion in soyawater (1:4) and was further diluted
with deionized water. Stock solutions (10 mM) of
capsazepine, AM251 (N-(piperidin-1-yl)-5-(4-iodophenyl)-
1-(2 ,4-dichlorophenyl) -4-methyl-1H -pyrazole-3-
c a r b ox am i d e ) , n ime s u l i d e (To c r i s ) , URB597
( 3 ′ - ( a m i n o c a r b o n y l ) [ 1 , 1 ′ - b i p h e n y l ] - 3 - y l ) -
cyclohexylcarbamate), RO1138452 (4,5-dihydro-N-[4-[[4-(1-
methylethoxy)phenyl]methyl]phenyl]-1H-imidazol-2-amine)
(Cayman Chemicals, Ann Arbor, MI, USA) and SR 144528
(N-[(1S)-endo-1,3,3-trimethyl bicyclo[2.2.1]heptan-2-yl]-
5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-
carboxamide) (Sanofi-Aventis, Montpellier, France) were pre-
pared in ethanol and further diluted in distilled water. U-46619
((5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxy-1-octenyl]-2-
oxabicyclo[2.2.1]hept-5-yl]-5-heptenoic acid) and O-1918
(1,3-dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-(1-
methylethenyl)-2-cyclohexen-1-yl]-benzene) (Cayman) were
supplied in methyl acetate, which was evaporated under a
stream of nitrogen, and ethanol was added as a solvent.
These agents were diluted to their final concentrations with
deionized water. Anti-FAAH antibodies were purchased from
Cayman (cat. no. 101600) and anti-β-actin and anti-rabbit IgG
alkaline phosphatase antibodies from Sigma-Aldrich (St.
Louis, MO, USA).
Calculations and statistical analysis
Contractile responses to U-46619 are shown as a percentage
of the contraction induced by 60 mM KCl (Kozłowska et al.
2007, 2008). Vasodilatory effects of anandamide or its solvent
are expressed as the percentage relaxation of the isometric
contraction induced by U-46619, 5-HT or KCl. In analogy to
our previous study (Baranowska-Kuczko et al. 2012), the
extent of relaxation at 100 μM anandamide was quantified
as a rough measure of the maximum extent of relaxation
obtainable (Rmax). Since some experimental procedures atten-
uated the Rmax of anandamide by more than 50 %, the con-
centrations causing a relaxation of 25 % of the pre-contracted
vessel were given (effective concentration for 25 % (EC25)
values). The half maximal effective concentration (EC50)
values (i.e. the concentrations causing a relaxation of 50 %
Table 1 Influence of various treatments on the relaxant effect to anandamide in endothelium-intact human pulmonary arteries pre-constricted with
U-46619, serotonin or KCl
Group n Tension (mN) pEC25 pEC50 Rmax (%)
a
Control (0.01–0.03 μM U-46619 pre-constricted) 21 10.0±0.4 5.7±0.1 5.0±0.1 90±7
–Endothelium 7 13.7±2.8 – – 23±11***
L-NAME (300) 4 10.0±1.1 4.2±0.1*** – 36±10***
Indomethacin (10) 7 10.7±1.8 – – 28±10***
L-NAME (300)+indomethacin (10) 3 8.4±0.8 – – 11±9***
RO1138452 (1) 5 10.0±2.0 4.5±0.3** – 30±5***
Iberiotoxin (0.1) 5 8.7±1.0 4.5±0.1*** – 39±8
URB597 (1) 12 12.9±1.5 5.1±0.2* 4.3±0.1** 65±3**
URB597 (1) + AM251 (1) 7 10.0±1.8 5.2±0.2 4.4±0.1 63±9
URB597 (1) + SR144528 (1) 6 10.9±2.2 4.8±0.2 4.7±0.1 76±10
URB597 (1) + capsazepine (1) 7 10.5±1.2 4.8±0.1 4.5±0.2 72±14
URB597 (1) + O-1918 (10) 7 10.3±1.5 4.4±0.1† – 38±3†
Control (ethanol 0.1 %v/v) 5 7.9±2.0 6.0±0.1 5.1±0.2 97±9
Nimesulide (10) 5 7.1±1.0 5.2±0.4* 4.5±0.1* 75±15
Control (1 μM serotonin pre-constricted) 5 8.8±0.5 5.3±0.2 4.8±0.1 85±8
Control (60 mM KCl pre-constricted) 5 11.4±2.5 – – 25±12°°°
Data are expressed as the mean ± SEM of n independent experiments
Some experiments were performed in endothelium-denuded rings (–endothelium). If not stated otherwise, micromolar concentrations of chemicals are
provided in brackets
L-NAME NG -nitro-L-arginine methyl ester
*P<0.05; **P<0.01; ***P<0.001, compared with the respective control group; †P<0.05, compared with URB597 alone; °°°P<0.001, compared with
the control obtained in the presence of U-46619
a Relaxant effect at the highest anandamide concentration (100 μM)
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of the pre-contracted vessel) were used when Rmax was at least
60 %. These values were calculated from the individual CRCs
and are usually expressed as their negative decadic logarithms
(pEC25 and pEC50).
The rightward shift of the CRC of anandamide by the
different experimental procedures (endothelium removal, en-
zyme blockers and receptor antagonists) was determined on
the basis of the EC25 values. The results are expressed as the
mean ± SEM of n experiments; n always refers to the number
of patients. For statistical analysis, Student’s t test for unpaired
data was used. For comparisons of the CRCs of two or more
treatment groups to the same control, analysis of variance
(ANOVA) followed by Dunnett’s test was performed (Prism
5, GraphPad Software, Inc., La Jolla, CA, USA). Differences
were considered significant when P<0.05.
Results
Influence of anandamide on the hPAs pre-constricted
with U-46619 or serotonin
The prostanoid TP receptor agonist U-46619 (0.001–0.3 μM)
induced a concentration-dependent contraction of hPA rings
(pEC50=7.7±0.1, n=3; Fig. 1). Anandamide 10 μM and its
vehicle Tocrisolve (1 μl/ml) did not modify the CRC of
U-46619 (pEC50=7.5±0.1, n=3; 7.5±0.1, n=4; Fig. 1) nor
did they affect the basal tone of hPA rings. In most experi-
ments, U-46619 was used to pre-contract the hPAs. The
tension generated by U-46619 at 0.01–0.03 μM (concentra-
tions approximately equivalent to its EC60) did not differ
significantly from that induced by 5-HT 1 μM (approximately
equivalent to its EC60; Kozłowska et al. 2007, 2008) or KCl
60 mM (Table 1).
Anandamide caused almost full relaxation of the hPAs pre-
constricted with U-46619 (Fig. 2); the pEC25 and pEC50
values were 5.7 and 5.0, respectively (Table 1). The vasodila-
tation induced by anandamide was gradual in onset. Thus, it
took 80 min to construct the whole CRCs. A typical trace of
anandamide-induced relaxations in U-46619-pre-constricted
arteries is shown in Fig. 2a. The following parameters had
virtually no influence on the anandamide-evoked relaxation:
use of 5-HT instead of U-46619 as pre-contracting agent
(Fig. 3a), smoking habits (Fig. 3b), sex (Fig. 3c) and age
(Fig. 3d).
Effects of endothelium removal and URB597
on the relaxation to anandamide
Removal of the endothelium very strongly reduced the vaso-
dilator effect of anandamide (Fig. 2b, Table 1). Pre-treatment
Fig. 1 Influence of anandamide and its solvent Tocrisolve on the con-
centration-dependent vasoconstriction induced by U-46619 in the endo-
thelium-intact human pulmonary artery. The results are expressed as
percentage of the isometric contraction induced by KCl 60 mM. Note
that anandamide (although relaxing pre-constricted vessels) did not affect
the basal tone. The mean ± SEM of three to four tissues for each curve is
presented. The SEM is smaller than or equal to the size of symbols in few
cases
Fig. 2 Representative original traces of the effects of anandamide and its
vehicle (Tocrisolve) (a) and influence of endothelium removal and
URB597 on the relaxant effect of anandamide in the human pulmonary
artery (b). a The experiments were performed in separate vessels obtained
from the same patient. The arrows indicate the application of the partic-
ular concentrations of anandamide or of its vehicle. b The results are
expressed as the percentage relaxation of the isometric contraction in-
duced by U-46619. The effects of Tocrisolve (0.001–1.0 %v/v; vehicle of
anandamide) are shown as well. The mean ± SEM of 3–21 tissues for
each curve is presented. The SEM is smaller than or equal to the size of
the symbols in few cases
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with the FAAH inhibitor URB597 (1 μM) attenuated the
anandamide-induced vasorelaxation in endothelium-intact
hPAs (Fig. 2b), yielding a rightward shift by a factor of 4.
Moreover, the effect elicited by the highest concentration of
the agonist was reduced by about 25 % (for pEC25 and Rmax
values, see Table 1).
Effects of L-NAME, COX inhibitors and RO1138452
on the relaxation to anandamide
As shown in Fig. 4a, the NO synthase inhibitor L-NAME
(300 μM) and the COX-1/COX-2 inhibitor indomethacin
(10 μM) given separately or in combination reduced by
about 55, 60 or 80 %, respectively, the relaxant effect
elicited by the highest concentration of anandamide
(100 μM) (for Rmax value, see Table 1). Moreover, L-
NAME shifted to the right of the CRC for anandamide
by a factor of 34 (for pEC25 value, see Table 1). The
selective COX-2 inhibitor nimesulide (10 μM) shifted to
the right of the CRC for anandamide by a factor of 6; the
effect elicited by the highest anandamide concentration
was reduced by about 20 % (Fig. 4b; for pEC25, pEC50
and Rmax values, see Table 1). The prostanoid IP receptor
antagonist RO1138452 (1 μM) shifted the CRC for anan-
damide to the right by a factor of 16 and reduced the
maximal effect of anandamide at 100 μM by about 60 %
(Fig. 4b; for pEC25 and Rmax values, see Table 1).
Effects of KCl and the K+ channel blocker iberiotoxin
on the relaxation to anandamide
In order to determine if potassium channels contribute to
the vasodilator effects of anandamide, some experiments
were carried out in KCl pre-constricted arteries and com-
pared with U-46619-pre-constricted vessels. The vasore-
laxation to anandamide at 100 μM was reduced by about
65 % in KCl pre-constricted arteries compared with
arteries pre-constricted with U-46619 (Fig. 5; for Rmax
value, see Table 1). Pre-treatment with the selective
blocker of big-conductance Ca2+-activated potassium
channels, iberiotoxin (0.1 μM), produced a 16-fold right-
ward shift of the CRC for anandamide in U-46619-pre-
constricted arteries; the effect of anandamide 100 μM
was reduced by 50 % (Fig. 5; pEC25 and Rmax values
in Table 1).
Effects of cannabinoid and TRPV1 receptor antagonists
on the relaxation to anandamide
As described above, the FAAH inhibitor URB597 (1 μM)
attenuated the anandamide-induced relaxation in hPAs
Fig. 3 Influence of the pre-
constricting agent (a), smoking
habits (b), sex (c) and age (d) of
the patients on the relaxant effect
of anandamide in the
endothelium-intact human
pulmonary artery. The results are
expressed as the percentage
relaxation of the isometric
contraction induced by serotonin
(5-HT) (a) or U-46619 (a–d).
Results are given as the mean ±
SEM of the number of tissues
(patients), namely a n=5 5-HT-
pre-constricted and n=21 U-
46619-pre-constricted, b 17
smokers and 4 non-smokers, c 6
women and 15 men and d 6
patients <60 years (54.4±1.2) and
15 patients >60 years (67.1±0.7;
P<0.001). Curves did not differ
with respect to the Rmax
(vasorelaxant effect of
anandamide 100 μM) and the
pEC50 (range of 4.8–5.1). The
SEM is smaller than or equal to
the size of symbols in few cases
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pre-constricted with U-46619. Therefore, the potential
involvement of cannabinoid and vanilloid receptors in
the vasodilatory response to anandamide was examined
in endothelium-intact hPAs treated with URB597. The
CB1 receptor antagonist AM251 (1 μM), the CB2 recep-
tor antagonist SR144528 (1 μM) and the TRPV1 receptor
antagonist capsazepine (1 μM) did not affect the
anandamide-induced relaxation (Fig. 6). On the other
hand, O-1918 (10 μM), an antagonist of the putative
endothelial cannabinoid receptor, produced a fivefold
rightward shift of the CRC for anandamide and reduced
the relaxant effect of the highest concentration of
anandamide (100 μM) by about 25 % (Fig. 6; for
pEC25 and Rmax values, see Table 1).
Expression of FAAH in the human pulmonary artery and lung
The expression of FAAH protein in the endothelium-intact
pulmonary artery (Fig. 7, lanes 1–3) and in the lung of humans
(Fig. 7, lanes 4–6) was analyzed by Western blotting with
polyclonal antibodies against FAAH. Western blot analysis
showed a single immunoreactive band of the molecular size
expected for FAAH (63 kDa) (Fig. 7).
Fig. 4 Influence of a indomethacin, NG-nitro-L-arginine methyl
ester (L-NAME) given separately or in combination, and b
nimesulide and RO1138452 on the relaxant effect of anandamide
in the endothelium-intact human pulmonary artery. The results are
expressed as the percentage relaxation of the isometric contraction
induced by U-46619. The control concentration-response curves
were obtained in the absence (related to indomethacin, L-NAME
and RO1138452) or presence of ethanol (related to nimesulide).
The mean ± SEM of 3–21 tissues for each curve is presented. The
SEM is smaller than or equal to the size of symbols in few cases
Fig. 5 Influence of KCl and iberiotoxin on the anandamide-induced
relaxation in the endothelium-intact human pulmonary artery. The results
are expressed as the percentage relaxation of the isometric contraction
induced by KCl (diamonds) and U-46619 (circles and inverted triangles).
The mean ± SEM of 5–21 tissues for each curve is presented. The SEM is
smaller than or equal to the size of symbols in few cases
Fig. 6 Influence of AM251, SR144528, capsazepine and O-1918 on the
relaxant effect of anandamide in the presence of URB597 (1 μM) in the
endothelium-intact human pulmonary artery. The results are expressed as
the percentage relaxation of the isometric contraction induced by
U-46619. The mean ± SEM of 6–12 tissues for each curve is presented.
The SEM is smaller than or equal to the size of symbols in few cases
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Discussion
The aim of the present study was to examine the receptor(s)
and mechanism(s) involved in the vasodilatory effect of AEA
in hPAs. The thromboxane analogue U-46619 was used as a
vasoconstrictor agent to facilitate comparisons with our work
on rat pulmonary arteries (Baranowska-Kuczko et al. 2012).
Moreover, thromboxane is important for the maintenance of
the pulmonary tone and implicated in the development of
PAH (Anderson and Nawarskas 2010).
In the present study, anandamide caused a slowly develop-
ing relaxation of the endothelium-intact hPAs yielding a Rmax
of ~90% and a pEC50 of ~5.0. The possibility that the relaxant
effect of anandamide is related to a direct antagonistic effect of
anandamide at prostanoid TP receptors in hPAs could be
excluded since anandamide at a concentration that evoked
~50 % relaxation (10 μM) did not influence the CRC of
U-46619. The fact that anandamide showed similar potencies
in preparations pre-contracted with U-46619 and serotonin
(pEC50 values of 5.0 and 4.8, respectively) also argues against
this possibility. A similar potency of anandamide was also
obtained in pulmonary arteries of the rat (pEC50 5.0;
Baranowska-Kuczko et al. 2012). Moreover, the potency of
anandamide in the hPAs resembled that of virodhamine
(pEC50 5.1; Kozłowska et al. 2008). As in our previous
studies, the concentrations of anandamide were in the micro-
molar range and similar to those occurring under pathophys-
iological conditions (Malinowska et al. 2012) when
endocannabinoid levels are enhanced and may be relevant
for vascular performance in pulmonary disorders.
The majority (~90 %) of hPAs used in our study was
obtained from smokers. This might mean that the effect of
anandamide represents an abnormal rather than the real phys-
iological response. This possibility, however, is very unlikely
since there was no difference in the response to this agonist in
tissue taken from smoking and non-smoking patients.
Moreover, the age and the sex of the patients do not influence
the anandamide-induced vasorelaxation.
Endothelium plays an important physiological role in the
regulation of smooth muscle tone in the pulmonary circula-
tion. We found that the relaxant effect of anandamide on the
hPAs is to a large extent endothelium-dependent. Thus, all
further experiments were carried out in rings with intact
endothelium. The NO synthase inhibitor L-NAME (300 μM;
Kozłowska et al. 2008) strongly inhibited the anandamide-
induced relaxation.
Anandamide is metabolized into arachidonic acid and eth-
anolamine by FAAH. Indeed, FAAHmetabolism products are
involved in the anandamide-induced relaxation in hPAs. First,
we showed the FAAH expression in human lungs and pulmo-
nary arteries (and could confirm the results obtained by Meng
et al. (2008) and Wenzel et al. (2013) on hPA smooth muscle
cells). Second, the FAAH inhibitor URB597 (1 μM;
Baranowska-Kuczko et al. 2012) reduced the anandamide-
evoked relaxation in the hPAs. The anandamide-derived ara-
chidonic acid may be converted via COX-1 and/or COX-2 to
vasoactive eicosanoids, yielding prostaglandins and prostacy-
clin. Both the non-selective COX inhibitor indomethacin
(10 μM; Baranowska-Kuczko et al. 2012) and the selective
COX-2 antagonist nimesulide (10 μM; Wahn et al. 2005)
diminished the anandamide-induced relaxation. The reason
why the attenuation of the vasorelaxation by selective COX-
2 inhibition was less marked when compared with combined
COX-1 plus COX-2 inhibition may be that an exposure to
anandamide lasting for >1 h is required to fully induce COX-2
expression (Chen et al. 2005).
In the pulmonary circulation, the IP receptor is detected (Li
et al. 2012) and prostacyclin is a particularly important prod-
uct of COX (Kuwano et al. 2008; Waxman and Zamanian
2013; Benyahia et al. 2013). We found that the IP receptor
antagonist RO1138452 (1 μM; Kozłowska et al. 2012;
Baranowska-Kuczko et al. 2012) reduced the anandamide-
mediated relaxation of the hPAs. Moreover, the extent of
attenuation of the anandamide-evoked relaxation is similar
to that obtained with indomethacin. Our data suggest that the
IP receptor is involved in the anandamide-mediated response
in the hPAs and are comparable to the results obtained in the
rat pulmonary arteries (pA2=6.2; Baranowska-Kuczko et al.
2012). Since the effect of L-NAME and indomethacin almost
equalled that of endothelial removal and the dual inhibition of
NO and COX-1/2 and almost completely abolish the effect of
anandamide, one can conclude that the endothelium-
dependent relaxation of the hPAs induced by anandamide is
mainly due to NO and COX-dependent pathways.
Two sets of experiments suggest the involvement of potas-
sium channels in the effect of anandamide. First, the relaxation
to anandamide was almost completely abolished in the hPAs
pre-constricted with a high concentration of KCl (60 mM;
Kozłowska et al. 2008). Such experimental conditions depo-
larize the hPAs by inhibiting the potassium ion efflux. Second,
iberiotoxin (0.1 μM; Galvez et al. 1990), a selective inhibitor
of the large-conductance calcium-dependent potassium chan-
nels, strongly reduced the relaxant effect of anandamide. The
BKCa channels may be activated by vasoactive anandamide
Fig. 7 Western blots for fatty acid amide hydrolase (FAAH) protein in
endothelium-intact human pulmonary arteries (lanes 1–3) and lungs
(lanes 4–6). Samples used for electrophoresis consisted of 100 μg of
protein of pooled tissue extracts (n=6) obtained from three different
experiments. The selectivity of the FAAH antibody was proved previ-
ously by Fowler et al. (2001). β-actin (43 kDa) was used as a loading
control
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degradation products (arachidonic acid and derivatives;
Gauthier et al. 2005) or by NO in the hPAs (Guerard et al.
2004). In addition, increased intracellular Ca2+ could release
endothelial vasorelaxants, including NO and PGI2 (Félétou
2009). It is therefore possible that COX-dependent products of
AEA-derived arachidonic acid induce the release of NO
which in turn acts in the hPA via KCa channel opening.
Anandamide mediates its cardiovascular effects through
cannabinoid CB1 and CB2 receptors, the O-1918-sensitive
endothelial cannabinoid receptor and the vanilloid TRPV1
receptor (Montecucco and Di Marzo 2012; Malinowska
et al. 2012). To eliminate the influence of anandamide metab-
olites, all experiments aimed at the determination of
cannabinoid-sensitive receptors were performed in the pres-
ence of URB 597 (1 μM). CB1 receptors are not involved in
the AEA-mediated vasorelaxation since the respective recep-
tor antagonist AM251 (1 μM; Wheal et al. 2010) did not
influence the CRC of anandamide. The involvement of CB2
and vanilloid TRPV1 receptors could also be excluded since
the respective antagonists at these receptors, SR144528
(1 μM; Kozłowska et al. 2008) and capsazepine (1 μM;
Tamaki et al. 2012), failed to modify the vasorelaxant effect
of anandamide. By contrast, O-1918 (10 μM; pA2=6.3 and
6.0; Kozłowska et al. 2008; Baranowska-Kuczko et al. 2012,
respectively) shifted to the right of the CRC for anandamide,
suggesting that this receptor plays a role in the anandamide-
induced vasorelaxation.
The quantitative role of unmetabolized anandamide ap-
pears to be lower than that played by the COX product. The
mechanism behind the vasodilator effect of unmetabolized
anandamide has not been studied in the present work; how-
ever, in our previous paper on the same preparation, abnormal
cannabidiol (which like anandamide activates the endothelial
cannabinoid receptor but is not metabolized) was shown to act
via the endothelium and the activation of Ca2+-activated po-
tassium channels (Kozłowska et al. 2007).
The present work (in combination with our previous stud-
ies: Kozłowska et al. 2007; 2008) on hPA is qualitatively
similar to our study on the rat pulmonary artery
(Baranowska-Kuczko et al. 2012); the extent of vasodilatation
was evenmoremarked in the human than in the rat pulmonary
artery. In those experiments, pre-constricted pulmonary arter-
ies were used; in non-pre-constricted vessels, anandamide had
no effect at all in pulmonary arteries of rats (Baranowska-
Kuczko et al. 2012), humans (present study) and mice
(Wenzel et al. 2013). In the isolated perfused lung of the
mouse (Wenzel et al. 2013) and the rabbit (Wahn et al.
2005), anandamide caused an increase in the perfusion pres-
sure (reflecting a vasopressor response). The isolated lung
model mainly reflects vessels of the pulmonary circulation
with a small calibre. Although the data obtained from the
isolated perfused lung are of particular interest with respect
to in vivo conditions, one has to consider that, in the
pulmonary unlike the systemic circulation, there are no typical
resistance vessels (Saouti et al. 2010). In order to have a
comprehensive view, it therefore appears necessary to consid-
er the contradictory results obtained on the pulmonary arteries
and in the isolated perfused lung preparation in combination.
The reason why anandamide acts so differently in the two
experimental models is unclear but it is of interest that this
endocannabinoid behaved as a vasodilator, vasoconstrictor or
was without vascular activity also in vessels of the systemic
circulation, depending on the calibre and/or the vascular tone
(White and Hiley 1998; Vanheel and Van de Voorde 2001).
With respect to the results in the pulmonary circulation, it is
intriguing that the pathways for vasodilatation and vasocon-
striction resemble each other. So, FAAH plays a role both for
endothelium-dependent vasodilatation (Baranowska-Kuczko
et al. 2012; present study) and endothelium-independent va-
soconstriction (Wahn et al. 2005; Wenzel et al. 2013). With
respect to the subsequent step, COX is implicated both in the
vasodilatation (Baranowska-Kuczko et al. 2012; present
study) and vasoconstriction (Wahn et al. 2005; Wenzel et al.
2013). Thus, one should be somewhat more cautious when
suggesting the potential use of FAAH inhibitors for the treat-
ment of PAH (Wenzel et al. 2013) or other diseases (e.g.
Bisogno and Maccarrone 2013).
Conclusions
In conclusion, our findings show that anandamide relaxes
hPAs. The vascular response to anandamide is almost totally
endothelium-dependent and involves the opening of potassi-
um channels and stimulation of NO release that, in turn, may
be the result of activation of the putative O-1918-sensitive
cannabinoid receptor or production of COX-sensitive
prostacyclin-like vasoactive products.
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